CM
ALDR

Crestline Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Crestline Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-132,658
Closed -$1.52M – 264
2017
Q4 		$1.52M Buy
+132,658
New +$1.48M 0.16% 55
2017
Q2 		– Sell
-25,500
Closed -$530K – 179
2017
Q1 		$530K Buy
+25,500
New +$565K 0.1% 83

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Crestline Management's ALDR Position: Q1 2018 in Review

Crestline Management sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 132,658 shares — an estimated $1.52M sold.

Crestline Management first reported a position in ALDR in Q1 2017 and held it in 2 quarters. The position peaked at $1.52M in Q4 2017. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Crestline Management reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Crestline Management sold 132,658 Alder Biopharmaceuticals shares in Q1 2018, an estimated $1.52M.
  • Crestline Management first reported a position in Alder Biopharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Crestline Management's Alder Biopharmaceuticals position peaked at $1.52M in Q4 2017.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Crestline Management's 13F filing for Q1 2018, filed 15 May 2018.